Skip to main content
Article thumbnail
Location of Repository

Nevirapine-associated early hepatotoxicity: incidence, risk factors, and associated mortality in a primary care ART programme in South Africa.

By Kathryn M Chu, Andrew M Boulle, Nathan Ford, Eric Goemaere, Valerie Asselman and Gilles Van Cutsem


BACKGROUND: The majority of antiretroviral treatment programmes in sub-Saharan Africa are scaling up antiretroviral treatment using a fixed dose first-line antiretroviral regimen containing stavudine, lamivudine, and nevirapine. One of the primary concerns with the use of this regimen is nevirapine-associated hepatotoxicity. METHODOLOGY/PRINCIPAL FINDINGS: Study participants were 1809 HIV-infected, antiretroviral naïve adults initiating nevirapine-based antiretroviral therapy between November 2002 and December 2006. The primary outcome was early hepatotoxicity. Secondary outcomes were associations with hepatotoxicity and mortality at six months. The cumulative proportion of early hepatotoxicity ranged from 1.0-2.0% giving an incidence-rate at 102 days of 3.6-7.6 per 100 person-years. Median time to hepatotoxicity was 32 (IQR 28-58) days. At 12 weeks, only 8% of patients had alanine aminotransferase monitoring at all the time-points recommended by national guidelines. No association was found between age, gender, baseline CD4 count, concurrent tuberculosis infection, prior participation in a prevention of mother-to-child-transmission program, or baseline weight and early hepatotoxicity. There was no association between early hepatotoxicity and mortality. CONCLUSIONS: The cumulative proportion of early hepatotoxicity in nevirapine based antiretroviral therapy was low in this resource-constrained setting. Hepatotoxicity was not associated with mortality. Frequent routine monitoring of alanine aminotransferase proved difficult to implement in this public sector primary care programme. Focused monitoring in the first month may be a more cost-effective and pragmatic option in settings with limited resources. Correlation with clinical signs and symptoms may allow future alanine aminotransferase testing to be dictated by clinical criteria

Year: 2010
DOI identifier: 10.1371/journal.pone.0009183
OAI identifier:
Provided by: MSF Field Research

Suggested articles


  1. (2003). A comprehensive hepatic safety analysis of nevirapine in different populations of HIV infected patients
  2. (2007). Analysis of severe hepatic events associated with nevirapine-containing regimens: CD4+ T-cell count and gender in hepatitis C seropositive and seronegative patients.
  3. (2008). Antiretroviral therapy in resource-limited settings
  4. (2007). Antiretroviralassociated toxicity among HIV-1-seropositive pregnant women in Mozambique receiving nevirapine-based regimens.
  5. (2007). Carr A
  6. (2007). Clinical toxicity of highly active antiretroviral therapy in a home-based AIDS care program in rural Uganda.
  7. (2004). Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study.
  8. (2006). Generic fixed-dose combination antiretroviral treatment in resource-poor settings: multicentric observational cohort.
  9. (2007). Hepatotoxicity during nevirapine-based fixed-dose combination antiretroviral therapy in kampala,
  10. (2001). Hepatotoxicity in HIV-1-infected patients receiving nevirapine-containing antiretroviral therapy.
  11. (2006). Highly active antiretroviral treatment containing efavirenz or nevirapine and related toxicity in the TREAT Asia HIV Observational Database.
  12. (2004). HIV drug nevirapine (Viramune): risk of severe hepatotoxicity.
  13. (2007). Medical Management of HIV Infection.
  14. (2006). Nevirapine toxicity.
  15. (2006). Nevirapine versus efavirenz in 742 patients: no link of liver toxicity with female sex, and a baseline CD4 cell count greater than 250 cells/microl.
  16. (2007). Nevirapine-associated toxicity in HIV-infected Thai men and women, including pregnant women.
  17. (2008). Nevirapine-associated toxicity in Niger.
  18. (2003). Risk and determinants of developing severe liver toxicity during therapy with nevirapine-and efavirenzcontaining regimens in HIV-infected patients.
  19. (2003). Risk of severe hepatotoxicity associated with antiretroviral therapy in the HIVNAT Cohort,
  20. (2003). Scaling Up Antiretroviral Therapy in Resource-Limited Settings. Treatment Guidelines for a Public Health Approach.
  21. (2005). Severe hepatotoxicity associated with nevirapine use in HIV-infected subjects.
  22. (2008). Spectrum of adverse events after generic HAART in southern Indian HIVinfected patients.
  23. (2008). The prevalence of hepatitis B co-infection in a South African urban government HIV clinic.
  24. Trials Group Division of AIDS for grading the severity of adult and pediatric adverse advents.
  25. (2005). Viramune Package Insert.

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.